← Back to all articles

Articles · Earnings, Guidance Tracker

Merck & Co. (MRK) Q3 2026 Earnings: Guidance Raised

Q3 2026 (ended Sep 30, 2026): revenue, EPS and full-year guidance from the SEC filing

Published Nov 5, 2026

TL;DR

  • Merck & Co. raised its full-year guidance; revenue +4.7% vs a year earlier.

Merck & Co.'s results for Q3 2026 (ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-10-29. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.

At a glance

ItemValue
Revenue (GAAP)$18,085 million (+4.7% vs a year earlier)
Diluted EPS (GAAP)$2.04
Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs)$2.49
Full-year guidanceRaised

Guidance

Merck narrowed 2026 sales to $66.8–$67.3 billion, raising the midpoint, and raised non-GAAP EPS to $2.77–$2.82 from $2.66–$2.76.

Why this label: 'Narrows and Raises' the sales range midpoint ($66.8-67.3B from $66.3-67.3B) and non-GAAP EPS range ($2.77-2.82 from $2.66-2.76); nothing core lowered.

MetricPeriodNewPrior (as stated in the release)
worldwide salesFY2026$66.8–$67.3 billion$66.3–$67.3 billion
non-GAAP EPSFY2026$2.77–$2.82$2.66–$2.76
non-GAAP operating expensesFY2026$42.4–$42.9 billion$42.0–$42.7 billion
non-GAAP effective tax rateFY202632.0%–33.0%35.0%–36.0%

From the release

Revenue: "Total Sales · $ · 18,085 · $ · 17,276 · 5 · %"

Earnings per share: "GAAP EPS Was $2.04; Non-GAAP EPS Was $2.49; GAAP and Non-GAAP EPS Include a One-Time Charge of $0.12 per Share Related to a Global License Agreement With SciBrunch"

worldwide sales: "Sales * · $66.8 billion to $67.3 billion · $66.3 billion to $67.3 billion"

non-GAAP EPS: "Non-GAAP EPS 3*** · $2.77 to $2.82 · $2.66 to $2.76"

non-GAAP operating expenses: "Operating expenses 3** · $42.4 billion to $42.9 billion · $42.0 billion to $42.7 billion"

Quotes are copied from the filing; in table rows, cell borders are shown as “·”.

Key fact: Raised 2026 non-GAAP EPS guidance to $2.77–$2.82 from $2.66–$2.76.

Source

Merck & Co. earnings release (SEC filing), accession 0001104659-26-119825, filed 2026-10-29.

Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.

Get the Sunday Recap by email

One email a week. Every issue is published on the site too, so this is only about getting it in your inbox.

Subscribing signs you up for the free YieldTerminal Sunday recap, one email a week. Educational only, not financial advice. Unsubscribe any time.

Educational commentary, not a recommendation to buy or sell anything.